Neurological involvement in SLE is mainly manifested as cerebrovascular accidents, seizures, cognitive impairment, headache and psychosis.1 In Saudi Arabia prevalence of SLE is estimated to be 19.28 per 100,000 population.2 In a retrospective analysis over a 10-year period, 51% of SLE patients were found to have neuropsychiatric manifestations.3 A study conducted by Al-Arfaj et al. showed neuropsychiatric manifestations in 27.6% of SLE patients in Saudi Arabia.4 Antiphospholipid antibodies (aPL) are a heterogeneous family of antibodies to phospholipids and phospholipid-binding proteins. The gene discussed is FASLG; the disease is systemic lupus erythematosus.